Engineered immune cells offer new hope for Hard-to-Treat leukemia
NCT ID NCT06649227
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether specially engineered immune cells (CAR-T cells) that target a protein called CD19 are safe for adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. Only patients whose leukemia cells show high levels of CD19 can join. The main goal is to check for serious side effects and early death not caused by the leukemia itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED ADULT AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Lille
RECRUITINGLille, 59000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune cell 'Bridge' offers new hope for tough leukemia
- New pill aims to keep leukemia away after transplant
- Experimental cocktail aims to beat back tough leukemia
- New pill shows promise for tough blood cancers in early trial
- New drug cocktail aims to beat back tough leukemia
- Engineered immune cells take on tough leukemia in early trial